CN101115759A - Cci-779多晶形物及其应用 - Google Patents

Cci-779多晶形物及其应用 Download PDF

Info

Publication number
CN101115759A
CN101115759A CNA200680004408XA CN200680004408A CN101115759A CN 101115759 A CN101115759 A CN 101115759A CN A200680004408X A CNA200680004408X A CN A200680004408XA CN 200680004408 A CN200680004408 A CN 200680004408A CN 101115759 A CN101115759 A CN 101115759A
Authority
CN
China
Prior art keywords
cci
polymorph
polymorph form
solid
bme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CNA200680004408XA
Other languages
English (en)
Chinese (zh)
Inventor
S·S·德什穆克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101115759A publication Critical patent/CN101115759A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA200680004408XA 2005-02-09 2006-01-25 Cci-779多晶形物及其应用 Withdrawn CN101115759A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65137405P 2005-02-09 2005-02-09
US60/651,374 2005-02-09

Publications (1)

Publication Number Publication Date
CN101115759A true CN101115759A (zh) 2008-01-30

Family

ID=36570939

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200680004408XA Withdrawn CN101115759A (zh) 2005-02-09 2006-01-25 Cci-779多晶形物及其应用

Country Status (19)

Country Link
US (1) US7442707B2 (enExample)
EP (1) EP1856130A1 (enExample)
JP (1) JP2008530090A (enExample)
KR (1) KR20070107030A (enExample)
CN (1) CN101115759A (enExample)
AR (1) AR052479A1 (enExample)
AU (1) AU2006213061A1 (enExample)
BR (1) BRPI0607932A2 (enExample)
CA (1) CA2595766A1 (enExample)
CR (1) CR9257A (enExample)
GT (1) GT200600044A (enExample)
IL (1) IL184560A0 (enExample)
MX (1) MX2007009590A (enExample)
NO (1) NO20073725L (enExample)
PE (1) PE20060996A1 (enExample)
RU (1) RU2007129264A (enExample)
TW (1) TW200638932A (enExample)
WO (1) WO2006086172A1 (enExample)
ZA (1) ZA200706628B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
RU2008120670A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
RU2008120712A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
KR20080077618A (ko) * 2005-12-07 2008-08-25 와이어쓰 정제된 결정체 ｃｃｉ-779 의 제조 방법
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
CN102282457A (zh) * 2009-01-21 2011-12-14 拜康有限公司 确定西罗莫司稳定性的方法和制备其稳定形式的工艺
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
EP1419154B1 (en) 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
PT1658295E (pt) * 2003-08-07 2007-09-25 Wyeth Corp Síntese regiosselectiva de cci-779
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
EP1737869A1 (en) * 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives

Also Published As

Publication number Publication date
US20060178392A1 (en) 2006-08-10
JP2008530090A (ja) 2008-08-07
NO20073725L (no) 2007-09-05
WO2006086172A1 (en) 2006-08-17
GT200600044A (es) 2006-11-09
CA2595766A1 (en) 2006-08-17
AU2006213061A1 (en) 2006-08-17
MX2007009590A (es) 2007-09-12
KR20070107030A (ko) 2007-11-06
RU2007129264A (ru) 2009-03-20
AR052479A1 (es) 2007-03-21
US7442707B2 (en) 2008-10-28
TW200638932A (en) 2006-11-16
BRPI0607932A2 (pt) 2016-11-08
EP1856130A1 (en) 2007-11-21
CR9257A (es) 2007-11-23
IL184560A0 (en) 2007-10-31
PE20060996A1 (es) 2006-11-13
ZA200706628B (en) 2010-01-27

Similar Documents

Publication Publication Date Title
US7282505B2 (en) Rapamycin polymorphs and uses thereof
US7446111B2 (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
JP2007522091A (ja) Ｃｃｉ−７７９アイソマーｃ
US7442707B2 (en) CCI-779 polymorph and use thereof
EP4027999A1 (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
EP2222666B1 (en) Crystalline polymorph of doxazosin mesylate (form iv) and process for preparation thereof
WO2018082596A1 (en) Solid forms of an adamantyl compound, compositions and uses thereof
US7553843B2 (en) Process for the preparation of purified crystalline CCI-779
JP2008524228A (ja) Ｘａ因子阻害剤の結晶フォーム
AU2021453749A1 (en) Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
CN121698864A (zh) R-四氢萘类脯氨酰羟化酶抑制剂晶体及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication